Cell 173, 1426–1438 (2018)
A promising approach in cancer immunotherapy is the use of T cells expressing chimeric antigen receptors (CARs), which consist of an antigen-specific single-chain fragment (scFv) linked to an intracellular signaling domain. Interaction of the CAR-expressing T cell with an antigen-specific tumor cell results in T-cell activation. However, the limited flexibility, specificity, and modularity of existing CARs require constant re-engineering of the T cells for new applications. To address some of these limitations, Cho et al. developed a split, universal and programmable (SUPRA) CAR system, zipCAR, composed of an extracellular leucine zipper fused to the intracellular signaling domain, while a zipFv component contained the complementary leucine zipper linked to the scFv. The level of SUPRA-mediated T-cell activation is determined on the basis of the affinity of the leucine zipper pairs, the expression levels of the zipCAR and zipFv, and the interaction between the T cell and the antigen-presenting cell. SUPRA also enables CAR inhibition by using a competitive zipFv containing a high-affinity leucine zipper, preventing zipFv–zipCAR interaction as well as combinatorial targeting of multiple antigens by adding different antigen-specific zipFv constructs. Overall, SUPRA offers improved utility and modality for cancer immunotherapy strategies.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Miura, G. ZIPing around CARs. Nat Chem Biol 14, 637 (2018). https://doi.org/10.1038/s41589-018-0093-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41589-018-0093-5